Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AdV-tk+ valacyclovir · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Study Arm | EXPERIMENTAL | AdV-tk + valacyclovir |
| Name | Type | Description |
|---|---|---|
| AdV-tk + valacyclovir | BIOLOGICAL | AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration. |
Inclusion Criteria: * Patients must have MPE (defined as positive pleural fluid cytology). Eligible patients include NSCLC, small cell lung cancer, malignant mesothelioma (MM), breast cancer and ovarian cancer. Diagnosis must be made prior to AdV-tk injection. For patients with MM, histologic proof...
AdV-tk is an investigational gene therapy being studied for use in oncology, specifically for pancreatic adenocarcinoma, malignant pleural effusion, malignant glioma, and glioma. It has been evaluated in Phase 1 clinical trials for these conditions, including pediatric brain tumors and pancreatic cancer.
AdV-tk is being developed by Candel Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol CADL.
AdV-tk is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for AdV-tk are Phase 1 studies.
AdV-tk has been studied in several completed Phase 1 trials, including NCT00634231 for pediatric brain tumors, NCT00638612 for pancreatic cancer, NCT01997190 for malignant pleural effusion, and NCT03576612 for high-grade gliomas.
AdV-tk is also known as GMCI, which stands for gene-mediated cytotoxic immunotherapy. In clinical trials, it has been referred to as GMCI when combined with other treatments like nivolumab and radiation therapy for gliomas.